| 摘要 |
<p>The present invention relates to novel uses of muteins or fragments (or variants thereof) derived from a lipocalin, e.g., a human tear lipocalin, that inhibit the binding of vascular endothelial growth factor (VEGF) to a VEGF receptor. Uses include methods of treating a disease or disorder caused or promoted by increased vascularisation in a subject, such as a wide range of cancer. The mutein may be a pharmaceutical composition, for example, and the pharmaceutical composition is safe and well tolerated when administered to a subject in an amount that is sufficient to yield a satisfactory therapeutic readout in said subject.</p> |
